BVNKF Company Profile and Key Details

PNK : BVNKF

Bavarian Nordic A/S

$21.20

At Close 4:00 PM

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Bavarian Nordic A/S (BVNKF) stock remained unchanged at $27.80 a share on OTC. The stock opened at $27.80, fluctuating between $27.80 to $27.80 during the session.

Stock Snapshot

27.8

Prev. Close

2.14B

Market Cap

27.8

Day Low

11.88

P/E Ratio

2.34

EPS (TTM)

1.85

Cash Flow per Share

27.8

Open

77.14M

Number of Shares

27.8

Day High

99.54%

Free Float in %

134.79

Book Value

100

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jun 17, 2026	27.80	27.80	27.80	27.80	100
May 28, 2026	27.82	27.82	27.82	27.82	250
May 19, 2026	30.29	30.29	30.29	30.29	5.03K
May 18, 2026	29.41	29.41	29.41	29.41	4
May 05, 2026	30.31	30.42	30.31	30.42	240
May 04, 2026	30.30	30.30	30.30	30.30	100
Apr 10, 2026	30.00	30.73	30.00	30.73	1.1K
Apr 06, 2026	31.29	31.29	31.29	31.29	160
Mar 30, 2026	29.71	29.71	29.71	29.71	1.63K
Mar 27, 2026	30.68	30.68	30.68	30.68	300
Mar 12, 2026	28.09	28.09	28.09	28.09	105
Feb 09, 2026	30.56	30.56	30.56	30.56	5
Jan 28, 2026	31.13	31.13	31.13	31.13	14
Jan 20, 2026	29.74	29.74	29.74	29.74	30
Dec 31, 2025	30.90	30.90	30.90	30.90	1.42K
Dec 29, 2025	30.00	30.00	30.00	30.00	108
Dec 10, 2025	30.65	30.65	30.65	30.65	100
Dec 09, 2025	30.32	30.32	30.32	30.32	100
Dec 08, 2025	29.44	29.44	29.44	29.44	2.56K
Dec 05, 2025	29.26	29.26	29.26	29.26	200

Contact Details

Hellerup, 2900

Denmark

https://www.bavarian-nordic.com 453 326 8383

About Company

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN (freeze-dried) that has completed Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase II clinical trial for the treatment of SARS-CoV-2; and TAEK-VAC, which is in Phase I/II clinical trial for treatment of advanced HER2 and brachyury-expressing cancers. It has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. The company operates in the United States, Belgium, Germany, the Netherlands, Sweden, Switzerland, Austria, the United Kingdom, Japan, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

Stock Peers

ODTC

Odonate Therapeutics, Inc.$2,849.50 GNMSF

Genmab A/S$268.61 CMXHF

CSL Limited$192.00 NONOF

Novo Nordisk A/S$144.95 CSLLY

0.75+0.79%

CSL Limited$95.35 UCBJY

-0.06-0.08%

UCB SA$73.15 PHMMF

4.3+16.01%

Pharma Mar, S.A.$31.15 NURPF

Neuren Pharmaceuticals Limited$14.00 ELOX

0.05+0.36%

Eloxx Pharmaceuticals, Inc.$13.98 TLPPF

Telix Pharmaceuticals Limited$11.00

Company Overview

The stock is currently mid-range between its 52-week high and low $26.08 and $37.60. With a market capitalization of about $2.14 billion, Bavarian Nordic A/S is classified as a mid-cap and shows market-like volatility (beta ~0.96). Key stats such as the average daily volume over the past year has been around 152.00 shares, volume is running light vs its 52-week average. Headquartered in Hellerup, None, Bavarian Nordic A/S operates in the Healthcare sector and the Biotechnology industry. Led by CEO Paul John Chaplin, the company employs approximately 1,645 people and listed since October 15, 2010. Bavarian Nordic A/S is a biopharmaceutical company primarily focused on the development, production, and commercialization of life-saving vaccines.

Technical Performance

Average 10-day trading volume of 100.00 shares is below the 3-month average of 890.80, indicating normal recent market interest.

Valuation Metrics

Bavarian Nordic A/S trades at a P/E ratio of 11.92, slightly below the S&P 500 average, with a price-to-sales ratio of 2.37 and a price-to-book ratio of 1.1 suggesting the stock is closer to book value. The P/FCF stands at 10.19, also above market averages.

Dividend & Fair Value

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Earnings & Analyst Outlook

Bavarian Nordic A/S earnings surprise history is a mixed track record. The quarter that ended March 12, 2026, missed forecasts by -9.71%. The prior quarter beat by 68.81%. Over the last six quarters, Apple has recorded several small beats. These include 72.74% in June 28, 2024.

Financial & Profitability Overview

Over the trailing twelve months, Bavarian Nordic A/S generated $7.06B in revenue, or $92.00 per share. Gross margin was 64.07%, operating margin 21.22%, and net profit margin 20.90%. Returns are healthy, with ROA at 10.28% and ROE at 14.27%.
On valuation metrics, Bavarian Nordic A/S trades at a P/E of 11.89, P/S of 2.36 and P/B of 1.10. The current ratio is 6.47 and quick ratio is 3.58. Operationally, the company’s inventory turnover is 1.17 and cash conversion cycle is 329.47 days. Debt-to-equity is 0.01, supported by a cash flow-to-debt ratio of 16.89.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Bavarian Nordic A/S posted revenue of $7.06B, down slightly from $3.15B in the prior quarter. Gross profit was $4.52B (margin 64.07%). Operating income was $1.50B (margin 21.2%). Net income was$1.48B (EPS $19.23).
The company ended the quarter with $1.87B in cash and short-term investments, a total debt of $145.30M, and net debt of - $1.33B. Total assets were $14.35B, with equity of $10.34B. Financials further reflected stability, with operating cash flow of $1.12B, free cash flow of $141.80M, and capital expenditures of - $977.41M.

Price Forecast & Outlook

Our AI price prediction model suggests that Bavarian Nordic A/S stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term.

Key Takeaways

Valuation shows Bavarian Nordic A/S trading at a premium to the broader market with a P/E of 11.92.

Frequently Asked Questions

What is the current Bavarian Nordic A/S (BVNKF) stock price?

Bavarian Nordic A/S (OTC: BVNKF) stock price is $27.80 in the last trading session. During the trading session, BVNKF stock reached the peak price of $27.80 while $27.80 was the lowest point it dropped to. The percentage change in BVNKF stock occurred in the recent session was 0% while the dollar amount for the price change in BVNKF stock was $0.00.

BVNKF's industry and sector of operation?

The OTC listed BVNKF is part of Biotechnology industry that operates in the broader Healthcare sector. Bavarian Nordic A/S designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of BVNKF?

No Data

How BVNKF did perform over past 52-week?

BVNKF's closing price is 21.49% higher than its 52-week low of $26.08 where as its distance from 52-week high of $37.60 is -33.85%.

How many employees does BVNKF have?

Number of BVNKF employees currently stands at 1,645.

Link for BVNKF official website?

Official Website of BVNKF is: https://www.bavarian-nordic.com

How do I contact BVNKF?

BVNKF could be contacted at phone 453 326 8383 and can also be accessed through its website. BVNKF operates from Philip Heymans Alle 3, Hellerup, 2900, Denmark.

How many shares of BVNKF are traded daily?

BVNKF stock volume for the day was 100 shares. The average number of BVNKF shares traded daily for last 3 months was 152.

What is the market cap of BVNKF currently?

The market value of BVNKF currently stands at $2.14B with its latest stock price at $27.80 and 77.14M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	1645
Beta	1.09
Sales or Revenue	$7.06B
5Y Sales Change%	6.498%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

BVNKF Company Profile and Key Details

Bavarian Nordic A/S

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Stock Snapshot

Valuation Metrics

Technical Performance

Company Overview

Earnings & Analyst Outlook

Dividend & Fair Value

Price Forecast & Outlook

Key Takeaways

Financial & Profitability Overview

Quarterly Financial Highlights